A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
At a glance
- Drugs Fasoracetam (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Aevi Genomic Medicine
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2017 According to Aevi Genomic Medicine media release, company anticipates announcing data from this study During the second half of 2017.